Invega Sustenna vs Vraylar
Side-by-side cost comparison based on Medicare Part D data
Invega Sustenna
Paliperidone Palmitate
Manufactured by Janssen
Vraylar
Cariprazine
Manufactured by AbbVie
Vraylar costs 75% less per claim than Invega Sustenna ($383.00 vs $1,513.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Invega Sustenna | Vraylar |
|---|---|---|
| Avg Cost Per Claim | $1,513.00 | $383.00 |
| Total Medicare Spending | $1.9B | $1.7B |
| Total Beneficiaries | 148,000 | 486,000 |
| Total Claims | 1,240,000 | 4,320,000 |
| Annual Cost/Patient | $12,676.00 | $3,403.00 |
| Year-over-Year Change | +4.2% | +26.3% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 17, 2029 |
| Manufacturer | Janssen | AbbVie |
| Condition | Mental Health | Mental Health |
| Generic Name | Paliperidone Palmitate | Cariprazine |
Invega Sustenna vs Vraylar: What the Data Shows
Invega Sustenna (Paliperidone Palmitate) and Vraylar (Cariprazine) are both used to treat mental health. Based on Medicare Part D data, Vraylar costs $383.00 per claim, which is 75% less than Invega Sustenna at $1,513.00 per claim.
Medicare spent $1.9B on Invega Sustenna and $1.7B on Vraylar. In terms of patient reach, Vraylar serves more beneficiaries (486,000 vs 148,000).
Year-over-year spending changed +4.2% for Invega Sustenna and +26.3% for Vraylar. Vraylar saw significant spending growth, suggesting increased utilization or price increases.
Invega Sustenna has a generic available, while Vraylar remains brand-only until its patent expires Sep 17, 2029.
Frequently Asked Questions
Vraylar is cheaper at $383.00 per claim, compared to $1,513.00 for Invega Sustenna. That makes Vraylar about 75% less expensive per claim based on Medicare Part D data.
Yes, both Invega Sustenna and Vraylar are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Invega Sustenna has a generic version (Paliperidone Palmitate) available, which is typically much cheaper. Vraylar is currently brand-only, with patent expiring Sep 17, 2029.
Medicare Part D spent $1.9B on Invega Sustenna covering 148,000 beneficiaries, and $1.7B on Vraylar covering 486,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.